

FILE 'HOME' ENTERED AT 17:52:54 ON 05 MAR 2003

=> index chemistry bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

INDEX 'AGRICOLA, ALUMINIUM, ANABSTR, APOLLIT, AQUIRE, BABS, BIOCOMMERCE,
BIOTECHNO, CABA, CAOLD, CAPLUS, CBNB, CEABA-VTB, CEN, CERAB, CIN,
COMPENDEX, CONFSCI, COPPERLIT, CORROSION, ENCOMPLIT, ENCOMPLIT2, FEDRIP,
GENBANK, INSPEC, INSPHYS, INVESTEXT, IPA, ...'

ENTERED AT 17:53:18 ON 05 MAR 2003

92 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s (growth (w) hormone) (s) (crystal? or crystalization)

5 FILE AGRICOLA
2 FILE ANABSTR
1 FILE APOLLIT
9 FILE BABS
2 FILE BIOCOMMERCE
70 FILE BIOTECHNO
15 FILE CABA
8 FILE CAOLD
118 FILE CAPLUS
1 FILE CBNB
2 FILE CEABA-VTB
2 FILE CEN
1 FILE CIN
2 FILE COMPENDEX

17 FILES SEARCHED...

13* FILE FEDRIP
16 FILE INSPEC
22 FILE INVESTEXT

31 FILES SEARCHED...

2 FILE NTIS
32 FILE PASCAL
7 FILE PROMT
2 FILE RAPRA
107 FILE SCISEARCH

44 FILES SEARCHED...

1 FILE ADISINSIGHT
1 FILE ADISNEWS
5 FILE AQUASCI
3 FILE BIOBUSINESS
124 FILE BIOSIS
9 FILE BIOTECHABS
9 FILE BIOTECHDS
40 FILE CANCERLIT
11 FILE DDFU
28 FILE DGENE
16 FILE DRUGU

65 FILES SEARCHED...

118 FILE EMBASE
55 FILE ESEIOBASE
2 FILE FSTA
20 FILE IFIPAT
42 FILE LIFESCI
119 FILE MEDLINE
3 FILE OCEAN
1 FILE PHIN

20 FILE TOXCENTER
86 FILES SEARCHED...
185 FILE USPATFULL
4 FILE USPAT2
1 FILE VETU
25 FILE WPIDS
25 FILE WPINDEX

47 FILES HAVE ONE OR MORE ANSWERS, 92 FILES SEARCHED IN STNINDEX

L1 QUE (GROWTH (W) HORMONE) (S) (CRYSTAL? OR CRYSTALIZATION)

=> file hits

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	4.95	5.16

FILE 'USPATFULL' ENTERED AT 17:58:41 ON 05 MAR 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'MEDLINE' ENTERED AT 17:58:41 ON 05 MAR 2003

FILE 'CAPLUS' ENTERED AT 17:58:41 ON 05 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'BIOTECHNO' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'LIFESCI' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'CANCERLIT' ENTERED AT 17:58:41 ON 05 MAR 2003

FILE 'PASCAL' ENTERED AT 17:58:41 ON 05 MAR 2003
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.

FILE 'DGENE' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WPIDS' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

FILE 'INVESTEXT' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 Thomson Financial Services, Inc. (TFS)

FILE 'IFIPAT' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 IFI CLAIMS(R) Patent Services (IFI)

FILE 'TOXCENTER' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 ACS

FILE 'INSPEC' ENTERED AT 17:58:41 ON 05 MAR 2003
Compiled and produced by the IEE in association with FIZ KARLSRUHE
COPYRIGHT 2003 (c) INSTITUTION OF ELECTRICAL ENGINEERS (IEE)

FILE 'DRUGU' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'CABA' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 CAB INTERNATIONAL (CABI)

FILE 'FEDRIP' ENTERED AT 17:58:41 ON 05 MAR 2003

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'BABS' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (c) 2003 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein Chemiedaten & Software GmbH and MDL Information Systems GmbH

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'CAOLD' ENTERED AT 17:58:41 ON 05 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PROMT' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 Gale Group. All rights reserved.

FILE 'AGRICOLA' ENTERED AT 17:58:41 ON 05 MAR 2003

FILE 'AQUASCI' ENTERED AT 17:58:41 ON 05 MAR 2003
(c) 2003 FAO (on behalf of the ASFA Advisory Board) All rights reserved.

FILE 'USPAT2' ENTERED AT 17:58:41 ON 05 MAR 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOBUSINESS' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 Biological Abstracts, Inc. (BIOSIS)

FILE 'OCEAN' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'ANABSTR' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (c) 2003 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'BIOCOMMERCE' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'CEABA-VTB' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (c) 2003 DECHEMA eV

FILE 'CEN' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'COMPENDEX' ENTERED AT 17:58:41 ON 05 MAR 2003
Compendex Compilation and Indexing (C) 2003
Elsevier Engineering Information Inc (EEI). All rights reserved.
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'NTIS' ENTERED AT 17:58:41 ON 05 MAR 2003
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2003)

FILE 'RAPRA' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 RAPRA Technology Ltd.

FILE 'FSTA' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 International Food Information Service

FILE 'APOLLIT' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (c) 2003 FIZ Karlsruhe

FILE 'CBNB' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (c) 2003 ELSEVIER ENGINEERING INFORMATION, INC.

FILE 'CIN' ENTERED AT 17:58:41 ON 05 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

FILE 'ADISINSIGHT' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 Adis International Ltd. (ADIS)

FILE 'ADISNEWS' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 Adis International Ltd. (ADIS)

FILE 'PHIN' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)

FILE 'VETU' ENTERED AT 17:58:41 ON 05 MAR 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

=> s l1

L2	185	FILE	USPATFULL
L3	124	FILE	BIOSIS
L4	119	FILE	MEDLINE
L5	118	FILE	CAPLUS
L6	118	FILE	EMBASE
L7	107	FILE	SCISEARCH
L8	70	FILE	BIOTECHNO
L9	55	FILE	ESBIOBASE
L10	42	FILE	LIFESCI
L11	40	FILE	CANCERLIT
L12	32	FILE	PASCAL
L13	28	FILE	DGENE
L14	25	FILE	WPIDS
L15	22	FILE	INVESTEXT
L16	20	FILE	IFIPAT
L17	20	FILE	TOXCENTER
L18	16	FILE	INSPEC
L19	16	FILE	DRUGU
L20	15	FILE	CABA

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'HORMONE) (S) '

L21	13	FILE	FEDRIP
L22	9	FILE	BABS
L23	9	FILE	BIOTECHDS
L24	8	FILE	CAOLD

L25	7	FILE	PROMT
L26	5	FILE	AGRICOLA
L27	5	FILE	AQUASCI
L28	4	FILE	USPAT2
L29	3	FILE	BIOBUSINESS
L30	3	FILE	OCEAN
L31	2	FILE	ANABSTR
L32	2	FILE	BIOCOMMERCE
L33	2	FILE	CEABA-VTB
L34	2	FILE	CEN
L35	2	FILE	COMPENDEX
L36	2	FILE	NTIS
L37	2	FILE	RAPRA
L38	2	FILE	FSTA
L39	1	FILE	APOLLIT
L40	1	FILE	CBNB
L41	1	FILE	CIN
L42	1	FILE	ADISINSIGHT
L43	1	FILE	ADISNEWS
L44	1	FILE	PHIN
L45	1	FILE	VETU

TOTAL FOR ALL FILES

L46 1261 L1

=> s l46 and caion? and (organic (w) solvent?)

L47	0	FILE	USPATFULL
L48	0	FILE	BIOSIS
L49	0	FILE	MEDLINE
L50	0	FILE	CAPLUS
L51	0	FILE	EMBASE
L52	0	FILE	SCISEARCH
L53	0	FILE	BIOTECHNO
L54	0	FILE	ESBIOBASE
L55	0	FILE	LIFESCI
L56	0	FILE	CANCERLIT
L57	0	FILE	PASCAL
L58	0	FILE	DGENE

<-----User Break----->

SEARCH ENDED BY USER

=> s l46 and cation? and (organic (w) solvent?)

L59	25	FILE	USPATFULL
L60	0	FILE	BIOSIS
L61	0	FILE	MEDLINE
L62	0	FILE	CAPLUS
L63	0	FILE	EMBASE
L64	0	FILE	SCISEARCH
L65	0	FILE	BIOTECHNO
L66	0	FILE	ESBIOBASE
L67	0	FILE	LIFESCI
L68	0	FILE	CANCERLIT
L69	0	FILE	PASCAL
L70	0	FILE	DGENE
L71	1	FILE	WPIDS
L72	0	FILE	INVESTEXT
L73	1	FILE	IFIPAT
L74	0	FILE	TOXCENTER
L75	0	FILE	INSPEC
L76	0	FILE	DRUGU
L77	0	FILE	CABA
L78	0	FILE	FEDRIP
L79	0	FILE	BABS
L80	0	FILE	BIOTECHDS

L81 0 FILE CACLD
 L82 0 FILE PRGMT
 L83 0 FILE AGRICOLA
 L84 0 FILE AQUASCI
 L85 1 FILE USPAT2
 L86 0 FILE BIOBUSINESS
 L87 0 FILE OCEAN
 L88 0 FILE ANABSTR
 L89 0 FILE BIOCOMMERCE
 L90 0 FILE CEABA-VTB
 L91 0 FILE CEN
 L92 0 FILE COMPENDEX
 L93 0 FILE NTIS
 L94 0 FILE RAPRA
 L95 0 FILE FSTA
 L96 0 FILE APOLLIT
 L97 0 FILE CBNB
 L98 0 FILE CIN
 L99 0 FILE ADISINSIGHT
 L100 0 FILE ADISNEWS
 L101 0 FILE PHIN
 L102 0 FILE VETU

TOTAL FOR ALL FILES

L103 29 L46 AND CATION? AND (ORGANIC (W) SOLVENT?)

=> D 1103 1-29 ibib abs

L103 ANSWER 1 OF 29 USPATFULL

ACCESSION NUMBER: 2003:30295 USPATFULL
 TITLE: Particles with improved solubilization capacity
 INVENTOR(S): Anderson, David, Colonial Heights, VA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003022242	A1	20030130
APPLICATION INFO.:	US 2002-176112	A1	20020621 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-300476P	20010623 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WHITHAM, CURTIS & CHRISTOFFERSON, P.C., 11491 SUNSET HILLS ROAD, SUITE 340, RESTON, VA, 20190	
NUMBER OF CLAIMS:	204	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	3885	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A particle is disclosed that comprises a first volume of hydrophobe-rich material with tunable dissolution and solubilization characteristics and a distinct second volume of nanostructured nonlamellar liquid crystalline material, said second volume containing said first domain and being capable of being in equilibrium with said first volume. Preferably, the nanostructured nonlamellar liquid crystalline material is capable of being in equilibrium with a polar solvent or a water-immiscible solvent or both.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 2 OF 29 USPATFULL

ACCESSION NUMBER: 2002:346976 USPATFULL
 TITLE: Methods of preparing carbohydrate crosslinked glycoprotein crystals

INVENTOR(S): Margolin, Alexey L., Newton, MA, United States
 Govardhan, Chandrika P., Lexington, MA, United States
 Visuri, Kalevi J., Kirkkonummi, FINLAND
 Uotila, Sinikka S., Espoo, FINLAND
 PATENT ASSIGNEE(S): Altus Biologics Inc., Cambridge, MA, United States
 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6500933	B1	20021231
APPLICATION INFO.:	US 2000-518849		20000303 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1998-US16372, filed on 6 Aug 1998 Continuation-in-part of Ser. No. US 1999-314717, filed on 19 May 1999, now patented, Pat. No. US 6359118 Continuation of Ser. No. US 1997-926279, filed on 5 Sep 1997, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Low, Christopher S. F.		
ASSISTANT EXAMINER:	Mohamed, Abdel A.		
LEGAL REPRESENTATIVE:	Fish & Neave, Haley, Jr., James F., Pierri, Margaret A.		
NUMBER OF CLAIMS:	13		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	1964		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the field of carbohydrate crosslinked glycoprotein crystals. Advantageously, such crosslinked glycoprotein crystals display stability to harsh environmental conditions, while maintaining the structural and functional integrity of the glycoprotein backbone. According to one embodiment, this invention relates to methods for concentrating proteins that have been modified by carbohydrates and for releasing their activity at controlled rates. This invention also provides methods for producing carbohydrate crosslinked glycoprotein crystals and methods for using them in pharmaceutical formulations, vaccines, immunotherapeutics, personal care compositions, including cosmetics, veterinary pharmaceutical compositions and vaccines, foods, feeds, diagnostics, cleaning agents, including detergents and decontamination formulations. The physical and chemical characteristics of carbohydrate crosslinked glycoprotein crystals render them particularly useful as sorbents for separations, such as chiral chromatography, or affinity chromatography--which are based on specific interactions between the active binding site of the glycoprotein component of the crystals and the substance or molecule of interest. Such characteristics also render carbohydrate crosslinked glycoprotein crystals useful as catalytic and binding components for the production of biosensing devices.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 3 OF 29 USPATFULL

ACCESSION NUMBER: 2002:344627 USPATFULL
 TITLE: THERAPEUTIC USE OF THE SMR 1 PROTEIN AND ACTIVE DERIVATIVES THEREOF
 INVENTOR(S): ROUGEOT, CATHERINE, CHEVREU, FRANCE
 ROUGEON, FRANCOIS, POIGNY LA FORET, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002198361	A1	20021226
APPLICATION INFO.:	US 1999-367703	A1	19991013 (9)
	WO 1998-EP956		19980219
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT, 1755		

JEFFERSON DAVIS HIGHWAY, FOURTH FLOOR, ARLINGTON, VA,
22202

NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Page(s)
LINE COUNT: 2466

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to the use of a peptide molecule consisting in a maturation product of SMR (Submandibular rat protein 1) of structural formula QHNPR, as well as the biologically active derivatives of the said peptide, for preventing or treating diseases associated with a mineral ion imbalance in a human or an animal body. More particularly, the present invention relates to the therapeutic use of the above-cited molecules for preventing or treating an hydromineral imbalance in organs and tissues such as kidney, bone, dental enamel, dental ivory, gut matrix, pancreas or glandular gastric mucosa. This invention also deals with therapeutic compositions comprising a pharmaceutically active amount of the above-described therapeutic molecules as well as with therapeutic methods using the said therapeutic compositions. Finally, the present invention relates to processes for selecting ligand molecules that possess an agonist or an antagonist biological activity on the target receptor of the QHNPR pentapeptide as well as to be selected ligand molecules themselves.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 4 OF 29 USPATFULL

ACCESSION NUMBER: 2002:290772 USPATFULL
TITLE: Human telomerase catalytic subunit: diagnostic and therapeutic methods
INVENTOR(S): Cech, Thomas R., Boulder, CO, United States
Lingner, Joachim, Epalinges, SWITZERLAND
Nakamura, Toru, Boulder, CO, United States
Chapman, Karen B., Sausalito, CA, United States
Morin, Gregg B., Palo Alto, CA, United States
Harley, Calvin B., Palo Alto, CA, United States
Andrews, William H., Richmond, CA, United States
PATENT ASSIGNEE(S): University Technology Corporation, Boulder, CO, United States (U.S. corporation)
Geron Corporation, Menlo Park, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6475789	B1	20021105
APPLICATION INFO.:	US 1997-912951		19970814 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-845050, filed on 9 May 1997, now patented, Pat. No. US 5743518 Continuation-in-part of Ser. No. US 1997-851843, filed on 6 May 1997, now patented, Pat. No. US 6093809 Continuation-in-part of Ser. No. US 1997-846017, filed on 25 Apr 1997, now abandoned Continuation-in-part of Ser. No. US 1997-844419, filed on 18 Apr 1997, now abandoned Continuation-in-part of Ser. No. US 1996-724643, filed on 1 Oct 1996, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Eyler, Yvonne		
ASSISTANT EXAMINER:	Andres, Janet L.		
LEGAL REPRESENTATIVE:	Schiff, J. Michael, Earp, David J., Ausenhus, Scott L.		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	40 Drawing Figure(s); 34 Drawing Page(s)		
LINE COUNT:	11465		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods related to human telomerase reverse transcriptase (hTERT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis, and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 5 OF 29 USPATFULL

ACCESSION NUMBER: 2002:251941 USPATFULL
TITLE: Carbohydrate crosslinked glycoprotein crystals
INVENTOR(S): Margolin, Alexey L., Newton, MA, UNITED STATES
Govardhan, Chandrika Poorna, Lexington, MA, UNITED STATES
Visuri, Kalevi, Kantvik, FINLAND
Uotila, Sinikka, Espoo, FINLAND
PATENT ASSIGNEE(S): Altus Biologics Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002137899	A1	20020926
APPLICATION INFO.:	US 2002-47605	A1	20020114 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-314717, filed on 19 May 1999, GRANTED, Pat. No. US 6359118 Continuation of Ser. No. US 1997-926279, filed on 5 Sep 1997, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	FISH & NEAVE, 1251 AVENUE OF THE AMERICAS, 50TH FLOOR, NEW YORK, NY, 10020-1105		
NUMBER OF CLAIMS:	55		
EXEMPLARY CLAIM:	1		
LINE COUNT:	2113		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the field of carbohydrate crosslinked glycoprotein crystals. Advantageously, such crosslinked glycoprotein crystals display stability to harsh environmental conditions, while maintaining the structural and functional integrity of the glycoprotein backbone. According to one embodiment, this invention relates to methods for concentrating proteins that have been modified by carbohydrates and for releasing their activity at controlled rates. This invention also provides methods for producing carbohydrate crosslinked glycoprotein crystals and methods for using them in pharmaceutical formulations, vaccines, immunotherapeutics, personal care compositions, including cosmetics, veterinary pharmaceutical compositions and vaccines, foods, feeds, diagnostics, cleaning agents, including detergents and decontamination formulations. The physical and chemical characteristics of carbohydrate crosslinked glycoprotein crystals render them particularly useful as sorbents for separations, such as chiral chromatography, or affinity chromatography--which are based on specific interactions between the active binding site of the glycoprotein component of the crystals and the substance or molecule of interest. Such characteristics also render carbohydrate crosslinked glycoprotein crystals useful as catalytic and binding components for the production of biosensing devices.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 6 OF 29 USPATFULL

ACCESSION NUMBER: 2002:251211 USPATFULL
TITLE: CONTROLLED DISSOLUTION CROSSLINKED PROTEIN CRYSTALS
INVENTOR(S): MARGOLIN, ALEXEY L., NEWTON, MA, UNITED STATES
PERSICETTI, ROSE A., STOW, MA, UNITED STATES
ST. CLAIR, NANCY L., ANN ARBOR, MI, UNITED STATES

KHALAF, NAZER K., Worchester, MA, UNITED STATES
SHENOY, BHAMI C., Woburn, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002137156	A1	20020926
APPLICATION INFO.:	US 1999-459395	A1	19991203 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1998-US7287, filed on 10 Apr 1998, UNKNOWN Continuation-in-part of Ser. No. US 1997-834661, filed on 11 Apr 1997, PATENTED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	FISH & NEAVE, MARGARET A PIERRI ESQ, 1251 AVENUE OF THE AMERICAS, NEW YORK, NY, 10020-1104		
NUMBER OF CLAIMS:	97		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Page(s)		
LINE COUNT:	3578		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to crosslinked protein crystals characterized by the ability to change from insoluble and stable form to soluble and active form upon a change in the environment of said crystals, said change being selected from the group consisting of change in temperature, change in pH, change in chemical composition, change from concentrate to dilute form, change in oxidation-reduction potential of the solution, change in the incident radiation, change in transition metal concentration, change in flouride concentration, change in free radical concentration, change in metal chelater concentration, change in shear force acting upon the crystals and combinations thereof. According to one embodiment of this invention, such crosslinked protein crystals are capable of releasing their protein activity at a controlled rate. This invention also provides methods for producing such crosslinked protein crystals, methods using them for protein delivery and methods using them in cleaning agents, including detergents, pharmaceutical compositions, vaccines, personal care compositions, including cosmetics, veterinary compositions, foods, feeds, diagnostics and formulations for decontamination.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 7 OF 29 USPATFULL

ACCESSION NUMBER: 2002:179201 USPATFULL
TITLE: Intermittent administration of a growth hormone secretagogue
INVENTOR(S): MacLean, David B., Providence, RI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002094992	A1	20020718
APPLICATION INFO.:	US 2001-940165	A1	20010827 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-229077P	20000830 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Gregg C. Benson, Pfizer Inc., Patent Department, MS 4159, Eastern Point Road, Groton, CT, 06340	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2898	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the intermittent administration of a growth hormone secretagogue to a patient.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 8 OF 29 USPATFULL

ACCESSION NUMBER: 2002:85540 USPATFULL
TITLE: STABILIZED PROTEIN CRYSTALS FORMULATIONS CONTAINING
THEM AND METHODS OF MAKING THEM
INVENTOR(S): MARGOLIN, ALEXEY L., NEWTON, MA, UNITED STATES
KHALAF, NAZAR K., WORCESTER, MA, UNITED STATES
CLAIR, NANCY L. ST., ANN ARBOR, MI, UNITED STATES
RAKESTRAW, SCOTT L., NEWARK, DE, UNITED STATES
SHENOY, BHAMI C., WOBURN, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002045582	A1	20020418
APPLICATION INFO.:	US 1999-374132	A1	19990810 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1999-US9099, filed on 27 Apr 1999, UNKNOWN Continuation-in-part of Ser. No. US 1998-224475, filed on 31 Dec 1998, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-83148P	19980427 (60)
	US 1997-70274P	19971231 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MARGARET A PIERRI, FISH & NEAVE, 1251 AVENUE OF THE AMERICAS, NEW YORK, NY, 100201104	
NUMBER OF CLAIMS:	187	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Page(s)	
LINE COUNT:	4131	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to methods for the stabilization, storage and delivery of biologically active macromolecules, such as proteins, peptides and nucleic acids. In particular, this invention relates to protein or nucleic acid crystals, formulations and compositions comprising them. Methods are provided for the crystallization of proteins and nucleic acids and for the preparation of stabilized protein or nucleic acid crystals for use in dry or slurry formulations. The present invention is further directed to encapsulating proteins, glycoproteins, enzymes, antibodies, hormones and peptide crystals or crystal formulations into compositions for biological delivery to humans and animals. According to this invention, protein crystals or crystal formulations are encapsulated within a matrix comprising a polymeric carrier to form a composition. The formulations and compositions enhance preservation of the native biologically active tertiary structure of the proteins and create a reservoir which can slowly release active protein where and when it is needed. Methods are provided preparing stabilized formulations using pharmaceutical ingredients or excipients and optionally encapsulating them in a polymeric carrier to produce compositions and using such protein crystal formulations and compositions for biomedical applications, including delivery of therapeutic proteins and vaccines. Additional uses for the protein crystal formulations and compositions of this invention involve protein delivery in human food, agricultural feeds, veterinary compositions, diagnostics, cosmetics and personal care compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 9 OF 29 USPATFULL

ACCESSION NUMBER: 2002:32187 USPATFULL
TITLE: THERAPEUTIC USE OF THE SMR1 PROTEIN, THE SMR1
MATURATION PRODUCTS, SPECIFICALLY THE QHNPR
PENTAPEPTIDE AS WELL AS ITS BIOLOGICALLY ACTIVE

INVENTOR(S): DERIVATIVES
ROUGEOT, CATHERINE, CHEVREUSE, FRANCE
ROUGEON, FRANCOIS, POIGUY LA FORET, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002019008	A1	20020214
APPLICATION INFO.:	US 1997-801405	A1	19970220 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	BURNS DOANE SWECKER & MATHIS L L P, POST OFFICE BOX 1404, ALEXANDRIA, VA, 22313-1404		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	8 Drawing Page(s)		
LINE COUNT:	2135		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention pertains to the use of a peptide molecule consisting in a maturation product of SMR1 (Submandibular rat protein 1) of structural formula QHNPR, as well as the biologically active derivatives of the said peptide, for preventing or treating diseases associated with a mineral ion imbalance in a human or an animal body. More particularly, the present invention relates to the therapeutic use of the above-cited molecules for preventing or treating an hydro-mineral imbalance in organs and tissues such as kidney, bone, dental enamel, dental ivory, gut matrix, pancreas or glandular gastric mucosa. This invention also deals with therapeutic compositions comprising a pharmaceutically active amount of the above-described therapeutic molecules as well as with therapeutic methods using the said therapeutic compositions. Finally, the present invention relates to processes for selecting ligand molecules that possess an agonist or an antagonist biological activity on the target receptor of the QHNPR pentapeptide as well as to the selected ligand molecules themselves.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 10 OF 29 USPATFULL

ACCESSION NUMBER: 2001:152708 USPATFULL
TITLE: Production of high titers of gibberellins, GA4 and GA7, by Gibberella fujikuroi strain LTB-1027
INVENTOR(S): Gallazzo, Jorge L., 1145 W. Knickerbocker Dr., Sunnyvale, CA, United States 94087
Lee, May D., 1335 Carbo Ct., Los Altos, CA, United States 94024

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6287800	B1	20010911
APPLICATION INFO.:	US 2000-645073		20000823 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-151770P	19990831 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Weber, Jon P.	
ASSISTANT EXAMINER:	Guttman, Harry J.	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
LINE COUNT:	519	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A new method of producing a mixture of gibberellins which is predominantly GA.sub.4 and GA.sub.7 but also contains GA.sub.3 has the steps of providing a seed of Gibberella fujikuroi Strain LTB-1027 or mutants derived therefrom, inoculating the seed into a culture medium

rich in carbohydrate and relatively low in nitrogen, incubating the culture for at least four days, separating the Gibberella fujikuroi Strain LTB-1027 from the culture broth, and extracting the gibberellins to produce a gibberellin mixture which is at least 50% GA.sub.4 and GA.sub.7. The method produces a gibberellin mixture in which the combined titer of GA.sub.4 and GA.sub.7 exceeds 800 mg/liter. The production method also produces a gibberellin mixture with approximately equal titers of gibberellins GA.sub.4 and GA.sub.7. A variation of the method produces a gibberellin mixture which contains over 40% GA.sub.4.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 11 OF 29 USPATFULL

ACCESSION NUMBER: 2001:114668 USPATFULL
 TITLE: CARBOHYDRATE CROSSLINKED GLYCOPROTEIN CRYSTALS
 INVENTOR(S): MARGOLIN, ALEXEY L., NEWTON, MA, United States
 GOVARDHAN, CHANDRIKA POORNA, LEXINGTON, MA, United States
 VISURI, KALEVI, KANTVIK, Finland

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001008934	A1	20010719
	US 6359118	B2	20020319
APPLICATION INFO.:	US 1999-314717	A1	19990519 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-926279, filed on 5 Sep 1997, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MARGARET A PIERRI, FISH & NEAVE, 1251 AVENUE OF THE AMERICAS, NEW YORK, NY, 10020		
NUMBER OF CLAIMS:	55		
EXEMPLARY CLAIM:	1		
LINE COUNT:	2109		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the field of carbohydrate crosslinked glycoprotein crystals. Advantageously, such crosslinked glycoprotein crystals display stability to harsh environmental conditions, while maintaining the structural and functional integrity of the glycoprotein backbone. According to one embodiment, this invention relates to methods for concentrating proteins that have been modified by carbohydrates and for releasing their activity at controlled rates. This invention also provides methods for producing carbohydrate crosslinked glycoprotein crystals and methods for using them in pharmaceutical formulations, vaccines, immunotherapeutics, personal care compositions, including cosmetics, veterinary pharmaceutical compositions and vaccines, foods, feeds, diagnostics, cleaning agents, including detergents and decontamination formulations. The physical and chemical characteristics of carbohydrate crosslinked glycoprotein crystals render them particularly useful as sorbents for separations, such as chiral chromatography, or affinity chromatography--which are based on specific interactions between the active binding site of the glycoprotein component of the crystals and the substance or molecule of interest. Such characteristics also render carbohydrate crosslinked glycoprotein crystals useful as catalytic and binding components for the production of biosensing devices.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 12 OF 29 USPATFULL

ACCESSION NUMBER: 2001:59977 USPATFULL
 TITLE: Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
 INVENTOR(S): Shalaby, Shalaby Wahba, Anderson, SC, United States
 Jackson, Steven A., Holliston, MA, United States

PATENT ASSIGNEE(S): Moreau, Jacques-Pierre, Upton, MA, United States
Societe de Conseils de Recherches et d'Applications
Scientifiques, SAS, Paris, France (non-U.S.
corporation)
Poly-Med Incorporated, Anderson, SC, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6221958	B1	20010424
APPLICATION INFO.:	US 1999-237405		19990126 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-867308, filed on 2 Jun 1997, now patented, Pat. No. US 5863985, issued on 26 Jan 1999 Continuation of Ser. No. US 464735 Continuation of Ser. No. WO 1994-US148, filed on 5 Jan 1994, now patented, Pat. No. WO 5672659, issued on 30 Sep 1997		

	NUMBER	DATE
PRIORITY INFORMATION:	IE 1993-930005	19930106
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Nutter, Nathan M.	
LEGAL REPRESENTATIVE:	Conway, John D., Morrill, Brian R. Fish & Richardson	
NUMBER OF CLAIMS:	42	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	1348	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a sustained release pharmaceutical composition. The composition includes a polyester containing a free COOH group ionically conjugated with a bioactive polypeptide comprising at least one effective ionogenic amine, wherein at least 50% by weight of the polypeptide present in the composition is ionically conjugated to the polyester.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 13 OF 29 USPATFULL

ACCESSION NUMBER: 2001:47617 USPATFULL
TITLE: Uses of oil bodies
INVENTOR(S): Deckers, Harm M, Calgary, Canada
van Rooijen, Gijs, Calgary, Canada
Boothe, Joseph, Calgary, Canada
Goll, Janis, Calgary, Canada
Mahmoud, Soheil, Calgary, Canada
Moloney, Maurice M., Calgary, Canada
PATENT ASSIGNEE(S): Sembiosys Genetics Inc., Calgary, Canada (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6210742	B1	20010403
APPLICATION INFO.:	US 2000-610855		20000705 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-84777, filed on 27 May 1998, now patented, Pat. No. US 6146645		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-47753P	19970527 (60)
	US 1997-47779P	19970528 (60)
	US 1998-75863P	19980225 (60)
	US 1998-75864P	19980225 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: Granted
PRIMARY EXAMINER: Dodson, Shelley A.
ASSISTANT EXAMINER: Lamm, Marina
LEGAL REPRESENTATIVE: Bereskin & Parr, Gravelle, Micheline
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1266

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel emulsion formulations which comprise oil bodies. The invention also provides a method for preparing the emulsions and the use of the emulsions in various domestic and industrial compositions. The emulsions are especially suited for the preparation of food products, personal care products, pharmaceutical products and industrial products.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 14 OF 29 USPATFULL

ACCESSION NUMBER: 2001:18010 USPATFULL
TITLE: Oil body based personal care products
INVENTOR(S): Deckers, Harm M., Calgary, Canada
van Rooijen, Gijs, Calgary, Canada
Boothe, Joseph, Calgary, Canada
Goll, Janis, Calgary, Canada
Moloney, Maurice M., Calgary, Canada
PATENT ASSIGNEE(S): Sembiosys Genetics Inc., Calgary, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6183762	B1	20010206
APPLICATION INFO.:	US 1999-448600		19991124 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-84777, filed on 27 May 1998		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-47753P	19970527 (60)
	US 1997-47779P	19970528 (60)
	US 1998-75863P	19980225 (60)
	US 1998-75864P	19980225 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Dodson, Shelley A.	
ASSISTANT EXAMINER:	Lamm, Marina	
LEGAL REPRESENTATIVE:	Bereskin & Parr	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	1774	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel emulsion formulations which comprise oil bodies. The invention also provides a method for preparing the emulsions and the use of the emulsions in various domestic and industrial compositions. The emulsions are especially suited for the preparation of food products, personal care products, pharmaceutical products and industrial products.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 15 OF 29 USPATFULL

ACCESSION NUMBER: 2000:174804 USPATFULL
TITLE: Telomerase catalytic subunit
INVENTOR(S): Cech, Thomas R., Boulder, CO, United States

PATENT ASSIGNEE(S): Lingner, Joachim, Boulder, CO, United States
University Technology Corporation, Boulder, CO, United States (U.S. corporation)
Geron Corporation, Menlo Park, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6166178		20001226
APPLICATION INFO.:	US 1997-974549		19971119 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-915503, filed on 14 Aug 1997, now abandoned And a continuation-in-part of Ser. No. US 1997-912951, filed on 14 Aug 1997 And a continuation-in-part of Ser. No. US 1997-911312, filed on 14 Aug 1997 which is a continuation-in-part of Ser. No. US 1997-854050, filed on 9 May 1997 which is a continuation-in-part of Ser. No. US 1997-851843, filed on 6 May 1997 which is a continuation-in-part of Ser. No. US 1997-846017, filed on 25 Apr 1997 which is a continuation-in-part of Ser. No. US 1997-844419, filed on 18 Apr 1997 which is a continuation-in-part of Ser. No. US 1996-724643, filed on 1 Oct 1996		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1997-US17618	19971001
	WO 1997-US17885	19971001
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Eyler, Yvonne	
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew LLP	
NUMBER OF CLAIMS:	1	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	128 Drawing Figure(s); 103 Drawing Page(s)	
LINE COUNT:	23874	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compositions and methods related to telomerase reverse transcriptase, the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 16 OF 29 USPATFULL

ACCESSION NUMBER: 2000:153280 USPATFULL
TITLE: Uses of oil bodies
INVENTOR(S): Deckers, Harm M, Calgary, Canada
van Rooijen, Gijs, Calgary, Canada
Boothe, Joseph, Calgary, Canada
Goll, Janis, Calgary, Canada
Mahmoud, Soheil, Calgary, Canada
Moloney, Maurice M., Calgary, Canada
PATENT ASSIGNEE(S): Sembiosys Genetics Inc., Calgary, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6146645		20001114
APPLICATION INFO.:	US 1998-84777		19980527 (9)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 1997-47753P 19970527 (60)
US 1997-47779P 19970528 (60)
US 1998-75863P 19980225 (60)
US 1998-75864P 19980225 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Dodson, Shelley A.
ASSISTANT EXAMINER: Lamm, Marina
LEGAL REPRESENTATIVE: Bereskin & Parr
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1330

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel emulsion formulations which comprise oil bodies. The invention also provides a method for preparing the emulsions and the use of the emulsions in various domestic and industrial compositions. The emulsions are especially suited for the preparation of food products, personal care products, pharmaceutical products and industrial products.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 17 OF 29 USPATFULL

ACCESSION NUMBER: 2000:121627 USPATFULL

TITLE: **Growth hormone crystals**
and a process for production of these GH-
crystals

INVENTOR(S): Junker, Flemming, Humleb.ae buttet.k, Denmark
Theisen, Claus Friis, K.o slashed.benhavn, Denmark

PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S.
corporation)

NUMBER KIND DATE

PATENT INFORMATION: US 6117984 20000912
APPLICATION INFO.: US 1998-63749 19980421 (9)
RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-350758, filed on 7 Dec
1994, now patented, Pat. No. US 5780599 which is a
continuation of Ser. No. US 1994-222515, filed on 1 Apr
1994, now abandoned which is a continuation of Ser. No.
US 961932

NUMBER DATE

PRIORITY INFORMATION: DK 1990-1687 19900713
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Moezie, F. T.
LEGAL REPRESENTATIVE: Zelson, Steve T., Gregg, Valeta
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 392

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Divalent **cation** crystals of human growth factor (hGH) or derivatives thereof, and pharmaceutical preparations comprising divalent **cation** crystals of hGH. In specific embodiments, the divalent **cation** is Zn++ and the molar ration Zn++ and hGH is about 0.2 to about 10.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 18 OF 29 USPATFULL

ACCESSION NUMBER: 1999:155679 USPATFULL
 TITLE: Human mutant tissue factor compositions useful as
 tissue factor antagonists
 INVENTOR(S): Ruf, Wolfram, San Diego, CA, United States
 Edgington, Thomas S., La Jolla, CA, United States
 PATENT ASSIGNEE(S): The Scripps Research Institute, La Jolla, CA, United
 States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5994296		19991130
APPLICATION INFO.:	US 1998-35241		19980305 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 416872		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Carlson, Karen Cochrane		
ASSISTANT EXAMINER:	Schnizer, Holly		
LEGAL REPRESENTATIVE:	Fitting, Thomas, Homes, Emily		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	2427		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes a mutant human tissue factor protein which binds functional Factor VII/VIIa but is substantially free of functional procoagulant cofactor activity, and compositions containing the mutant protein. Also disclosed are methods for using the mutant human tissue factor proteins, and recombinant DNA vectors for expressing the protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 19 OF 29 USPATFULL
 ACCESSION NUMBER: 1999:12993 USPATFULL
 TITLE: Ionic molecular conjugates of biodegradable polyesters
 and bioactive polypeptides
 INVENTOR(S): Shalaby, Shalaby W., Pendleton, SC, United States
 Jackson, Steven A., Holliston, MA, United States
 Moreau, Jacques-Pierre, Upton, MA, United States
 PATENT ASSIGNEE(S): Kinerton Limited, Dublin, Ireland (non-U.S.
 corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5863985		19990126
APPLICATION INFO.:	US 1997-867308		19970602 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-464735, filed on 29 Jun 1995, now patented, Pat. No. US 5672659		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Nutter, Nathan M.		
LEGAL REPRESENTATIVE:	Conway, John D. Fish & Richardson		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	959		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a sustained release pharmaceutical composition. The composition includes a polyester containing a free COOH group ionically conjugated with a bioactive polypeptide comprising at least one effective ionogenic amine, wherein at least 50% by weight of the polypeptide present in the composition is ionically conjugated to the polyester.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 20 OF 29 USPATFULL

ACCESSION NUMBER: 1998:157309 USPATFULL
TITLE: Pharmaceutical formulation
INVENTOR(S): S.o slashed.rensen, Hans Holmegaard, Virum, Denmark
Skriver, Lars, Ved.ae butted.k, Denmark
Hoelgaard, Annie Rassing, Holte, Denmark
PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5849704		19981215
APPLICATION INFO.:	US 1995-458386		19950602 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-12817, filed on 3 Feb 1993 which is a continuation-in-part of Ser. No. US 1992-827200, filed on 28 Jan 1992		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1991-2046	19911220
	DK 1992-1364	19921110
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Schain, Howard E.	
ASSISTANT EXAMINER:	Touzeau, Lynn	
LEGAL REPRESENTATIVE:	Zelson, Steve T., Argis, Cheryl H.	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	1071	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical preparation comprising a **growth hormone** and histidine or a derivative of histidine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature. **Crystallization of growth hormone** in the presence of histidine or a derivative thereof gives rise to a higher yield of **crystals** having a higher purity than known methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 21 OF 29 USPATFULL

ACCESSION NUMBER: 1998:157305 USPATFULL
TITLE: Pharmaceutical formulation
INVENTOR(S): S.o slashed.rensen, Hans Holmegaard, Virum, Denmark
Skriver, Lars, Ved.ae butted.k, Denmark
Hoelgaard, Annie Rassing, Holte, Denmark
PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, Denmark (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5849700		19981215
APPLICATION INFO.:	US 1995-458385		19950602 (8)
DISCLAIMER DATE:	20181215		
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-12817, filed on 3 Feb 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-827200, filed on 28 Jan 1992, now abandoned		

NUMBER	DATE
--------	------

PRIORITY INFORMATION: DK 1991-2046 19911220
DK 1992-1364 19921110
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Tsang, Cecilia J.
ASSISTANT EXAMINER: Touzeau, P. Lynn
LEGAL REPRESENTATIVE: Zelson, Esq., Steve T., Agris, Esq., Cheryl H.
NUMBER OF CLAIMS: 15
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 1020

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical preparation comprising a **growth hormone** and histidine or a derivative of histidine as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved preparation at ambient temperature. **Crystallization of growth hormone** in the presence of histidine or a derivative thereof gives rise to a higher yield of **crystals** having a higher purity than known methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 22 OF 29 USPATFULL

ACCESSION NUMBER: 1998:85943 USPATFULL
TITLE: Methods for treating cancer and other cell proliferative diseases
INVENTOR(S): Schlessinger, Joseph, New York, NY, United States
Lax, Irit, Fair Lawn, NJ, United States
Ladbury, John E., New York, NY, United States
Tang, Peng Cho, Moraga, CA, United States
PATENT ASSIGNEE(S): Sugan, Inc., Redwood City, CA, United States (U.S. corporation)
New York University, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5783568		19980721
APPLICATION INFO.:	US 1994-258307		19940610 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Fonda, Kathleen K.		
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 7 Drawing Page(s)		
LINE COUNT:	1440		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method of treating in a mammal certain cancers, other cell proliferative diseases, and/or angiogenesis by using a salt or complex of a sulfated saccharide. The invention also relates to the use of mutant heparin binding growth factors that bind to the growth factor receptor, but not to heparin. The invention also provides pharmaceutical compositions for such methods.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 23 OF 29 USPATFULL

ACCESSION NUMBER: 1998:82875 USPATFULL
TITLE: **Growth hormone crystals**
and a process for production of **growth**

INVENTOR(S): **hormone crystals**
Junker, Flemming, Humleb.ae butted.k, Denmark
Theisen, Claus Friss, K.o slashed.benhavn, Denmark
PATENT ASSIGNEE(S): Novo Nordisk A/S, BAGSVAERD, Denmark (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5780599		19980714
APPLICATION INFO.:	US 1994-350758		19941207 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-222515, filed on 1 Apr 1994, now abandoned which is a continuation of Ser. No. US 1993-961932, filed on 13 Jan 1993, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	DK 1990-1687	19900713
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Sayala, Chhaya D.	
LEGAL REPRESENTATIVE:	Zelson, Esq., Steve T., Gregg, Esq., Valeta	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Figure(s); 1 Drawing Page(s)	
LINE COUNT:	440	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of producing chemically stable and biologically active **growth hormone crystals** and processes for production of pharmaceutical preparations containing these **growth hormone crystals**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 24 OF 29 USPATFULL

ACCESSION NUMBER: 1998:34044 USPATFULL
TITLE: Process for manufacturing **crystals** of **growth hormone** and **crystals** thereby obtained

INVENTOR(S): Florin-Robertsson, Ebba, Stockholm, Sweden
Hokby, Elvy, Enskede, Sweden
Lundin, Ronny, Ekero, Sweden
Thome, Sirkka, Stockholm, Sweden
Westin-Sjodahl, Gertrud, Sodertalje, Sweden
PATENT ASSIGNEE(S): Pharmacia & Upjohn Aktiebolag, Stockholm, Sweden
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5734026		19980331
	WO 9410192		19940511
APPLICATION INFO.:	US 1995-424450		19950524 (8)
	WO 1993-SE885		19931027
			19950524 PCT 371 date
			19950524 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	SE 1992-3175	19921028
	SE 1993-2278	19930702
	SE 1993-885	19931027
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Ulm, John	
ASSISTANT EXAMINER:	Sacud, Christine	
LEGAL REPRESENTATIVE:	Pollock, Vande Sande & Priddy	

NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 624

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for manufacturing **crystals** of **growth hormone** (GH) comprising the steps of:

i) mixing GH with an aqueous solution comprising a buffer and a chemical compound with the general formula (1):

Ar--[--CR.sub.1 R.sub.2 --]n--[--C R.sub.3 R.sub.4 --]m--C R.sub.5
R.sub.6 --OH (1)

in which Ar is phenyl, alkyl-substituted phenyl, naphthyl, or alkyl-substituted naphthyl, R.sub.1 to R.sub.6 is H, OH or alkyl and n and m is 0 or 1;

ii) incubating; and

iii) isolating the crystals is provided. The crystals are in the form of needles, trigonal forms, cubes or parallelepipeds with a length of at least 20 microns.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 25 OF 29 USPATFULL

ACCESSION NUMBER: 1998:25203 USPATFULL
TITLE: Human mutant tissue factor compositions useful as tissue factor antagonists
INVENTOR(S): Ruf, Wolfram, San Diego, CA, United States
Edgington, Thomas S., La Jolla, CA, United States
PATENT ASSIGNEE(S): The Scripps Research Institute, La Jolla, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5726147		19980310
	WO 9428017		19941208
APPLICATION INFO.:	US 1995-416872		19950418 (8)
	WO 1994-US6197		19940601
			19950418 PCT 371 date
			19950418 PCT 102(e) date
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-70154, filed on 1 Jun 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Fitzgerald, David L.		
ASSISTANT EXAMINER:	Kemmerer, Elizabeth C.		
LEGAL REPRESENTATIVE:	Fitting, Thomas, Holmes, Emily		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 5 Drawing Page(s)		
LINE COUNT:	2370		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes a mutant human tissue factor protein which binds functional Factor VII/VIIa but is substantially free of functional procoagulant cofactor activity, and compositions containing the mutant protein. Also disclosed are methods for using the mutant human tissue factor proteins, and recombinant DNA vectors for expressing the protein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 26 OF 29 USPATFULL

ACCESSION NUMBER: 97:89035 USPATFULL
 TITLE: Ionic molecular conjugates of biodegradable polyesters
 and bioactive polypeptides
 INVENTOR(S): Shalaby, Shalaby W., Pendleton, SC, United States
 Jackson, Steven A., Holliston, MA, United States
 Moreau, Jacques-Pierre, Upton, MA, United States
 PATENT ASSIGNEE(S): Kinerton Limited, Ireland (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5672659		19970930
	WO 9415587		19940721
APPLICATION INFO.:	US 1995-464735		19950629 (8)
	WO 1994-US148		19940105
			19950629 PCT 371 date
			19950629 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	IE 1993-930005	19930106
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Nutter, Nathan M.	
LEGAL REPRESENTATIVE:	Fish & Richardson P.C., McGowan, William E.	
NUMBER OF CLAIMS:	32	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	985	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition including a polyester containing one or more free COOH groups ionically conjugated with a bioactive polypeptide comprising at least one effective ionogenic amine, wherein the polyester contains a member selected from the group of L-lactic acid, D-lactic acid, DL-lactic acid, .epsilon.-caprolactone, p-dioxanone, .epsilon.-caprolic acid, alkylene oxalate, cycloalkylene oxalate, alkylene succinate, .beta.-hydroxybutyrate, substituted or unsubstituted trimethylene carbonate, 1,5-dioxopan-2-one, 1,4-dioxepan-2-one, glycolide, glycolic acid, L-lactide, D-lactide, DL-lactide, meso-lactide, and any optically active isomers, racemates or copolymers thereof, and at least 50%, by weight, of the polypeptide present in the composition is ionically conjugated to said polyester.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L103 ANSWER 27 OF 29 WPIDS (C) 2003 THOMSON DERWENT
 ACCESSION NUMBER: 1992-056826 [07] WPIDS
 DOC. NO. CPI: C1992-025665
 TITLE: **Cationic crystals** of (pref. human) **growth hormone** - produced by adding inorganic or organic **cations** to **growth hormone** soln. at pH 5-8, growing and isolating **crystals**.
 DERWENT CLASS: B04
 INVENTOR(S): JUNKER, F; THEISEN, C F; THEISEN, C
 PATENT ASSIGNEE(S): (NOVO) NOVO-NORDISK AS; (NOVO) NOVO NORDISK AS
 COUNTRY COUNT: 39
 PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WD 9200998	A	19920123 (199207)*			
RW: AT BE CH DE DK ES FR GB GR IT LU NL SE					
W: AU BG BR CA CS FI HU JP KP KR LK MC MG MW NO PL RO SD SU US					
ZA 9105446	A	19920325 (199218)		18	
AU 9182846	A	19920204 (199220)			

PT 98297 A 19920529 (199227)
 EP 540582 A1 19930512 (199319) EN 18
 R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE
 NZ 238904 A 19930428 (199320)
 JP 05507497 W 19931028 (199348) 7
 HU 64086 T 19931129 (199401)
 EP 540582 B1 19940831 (199433) EN 15
 R: AT BE CH DE DK ES FR GB GR IT LI LU NL SE
 DE 69103755 E 19941006 (199439)
 ES 2060399 T3 19941116 (199501)
 HU 210323 B 19950328 (199518)
 AU 666465 B 19960215 (199614)
 IE 67054 B 19960221 (199617)
 JP 2524446 B2 19960814 (199637) 6
 US 5780599 A 19980714 (199835)
 RU 2108341 C1 19980410 (199846)
 CA 2086087 C 19990914 (200004) EN
 US 6117984 A 20000912 (200046)

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
ZA 9105446	A	ZA 1991-5446	19910712
AU 9182846	A	AU 1991-82846	19910712
		WO 1991-DK203	19910712
PT 98297	A	PT 1991-98297	19910711
EP 540582	A1	EP 1991-913240	19910712
		WO 1991-DK203	19910712
NZ 238904	A	NZ 1991-238904	19910710
JP 05507497	W	JP 1991-512511	19910712
		WO 1991-DK203	19910712
HU 64086	T	WO 1991-DK203	19910712
		HU 1993-67	19910712
EP 540582	B1	EP 1991-913240	19910712
		WO 1991-DK203	19910712
DE 69103755	E	DE 1991-603755	19910712
		EP 1991-913240	19910712
		WO 1991-DK203	19910712
ES 2060399	T3	EP 1991-913240	19910712
HU 210323	B	WO 1991-DK203	19910712
		HU 1993-67	19910712
AU 666465	B	AU 1991-82846	19910712
IE 67054	B	IE 1991-2444	19910712
JP 2524446	B2	JP 1991-512511	19910712
		WO 1991-DK203	19910712
US 5780599	A Cont of	WO 1991-DK203	19910712
	Cont of	US 1993-961932	19930113
	Cont of	US 1994-222515	19940401
		US 1994-350758	19941207
RU 2108341	C1	WO 1991-DK203	19910712
		RU 1993-5051	19910712
CA 2086087	C	CA 1991-2086087	19910712
		WO 1991-DK203	19910712
US 6117984	A Cont of	WO 1991-DK203	19910712
	Cont of	US 1993-961932	19930113
	Cont of	US 1994-222515	19940401
	Cont of	US 1994-350758	19941207
		US 1998-63749	19980421

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 9182846	A Based on	WO 9200998

EP 540582	A1	Based on	WO 9200998
JP 05507497	W	Based on	WO 9200998
HU 64086	T	Based on	WO 9200998
EP 540582	B1	Based on	WO 9200998
DE 69103755	E	Based on	EP 540582
		Based on	WO 9200998
ES 2060399	T3	Based on	EP 540582
HU 210323	B	Previous Publ.	HU 64086
		Based on	WO 9200998
AU 666465	B	Previous Publ.	AU 9182846
		Based on	WO 9200998
JP 2524446	B2	Previous Publ.	JP 05507497
		Based on	WO 9200998
CA 2086087	C	Based on	WO 9200998
US 6117984	A	Cont of	US 5780599

PRIORITY APPLN. INFO: DK 1990-1687 19900713

AN 1992-056826 [07] WPIDS

AB WO 9200998 A UPAB: 19931006

Prod'n. of **cation crystals** of **growth**

hormone (GH) or its derivs. comprises: (a) adding inorganic or organic **cations** to a soln. of GH at pH 5-8; (b) growing **crystals** at a temp. of 0-30 deg C; and (c) isolating the **cation crystals** by known means. Also claimed are **cation crystals** of GH or its derivs..

The pH is 5.0-7.5, pref. 5.0-6.8, or 5.8-6.5, pref. 6.0-6.5. The **organic solvent** is selected from short-chained aliphatic, cyclic or aromatic alcohols or ketones pref. ethanol or acetone, or methanol or 2-propanol, and is added at 0.1-50% v/v, pref. 0.1-30%, esp. 6-12%. The **cation** is divalent, pref. Zn(2+), and is added in a concn. below the limit for unspecific pptn. of amorphous material i.e. 0.5-10 molZn(2+)/mol. GH, pref. 1.1-2.2, esp. 1.2-2.0. The temp. is pref. 4-25 deg C. The molar ratio of Zn(2+):GH is 0.2:10, pref. 0.5:5, pref. 0.5:2.0.

USE/ADVANTAGE - The process is used as a purificn. and/or isolation step in the mfr. of GH used in pharmaceutical preps. GHs derived from humans, bovines, porcines, ovines, salmon, trout or tuna may be purified, pref. humans. The process is fast, efficient and downstream, and as the crystals are highly stable they are produced ready to use without need for reconstitution.

0/1

ABEQ EP 540582 A UPAB: 19931113

Prod'n. of **cation crystals** of **growth**

hormone (GH) or its derivs. comprises: (a) adding (in)organic **cations** to a soln. of GH at pH 5-8; (b) growing **crystals** at a temp. of 0-30 deg.C; and (c) isolating the **cation crystals** by known means.

The pH is 5.0-7.5, pref. 5.0-6.8 or 5.8-6.5, pref. 6.0-6.5.

Organic solvent is short-chained aliphatic, cyclic or aromatic alcohols or ketones pref. ethanol or acetone, or methanol or 2-propanol, and is added at 0.1-50% v/v, pref. 0.1-30% esp. 6-12%.

Cation is divalent, pref. Zn(2+), and is added in a concn. below the limit for unspecific pptn. of amorphous material i.e. 0.5-10 mol. Zn(2+)/mol. GH, pref. 1.1-2.2, esp. 1.2-2.0. Temp. is pref. 4-25 deg.C.. Molar ratio of Zn(2+): GH is 0.2:10, pref. 0.5:5, pref. 0.5:2.0.

USE/ADVANTAGE - As a purificn. and/or isolation step in the mfr. of GH used in pharmaceutical preps. GHs derived from humans, bovines, porcines, ovines, salmon, trout or tuna may be purified, pref. humans. Process is fast, efficient and downstream, and as the crystals are highly stable they are produced ready to use without need for reconstitution.

ABEQ JP 05507497 W UPAB: 19940120

Prod'n. of **cation crystals** of **growth**

hormone (GH) or its derivs. comprises: (a) adding inorganic or organic **cations** to a soln. of GH at pH 5-8; (b) growing **crystals** at a temp. of 0-30 deg.C; and (c) isolating the

cation crystals by known means. Also claimed are **cation crystals** of GH or its derivs..

The pH is 5.0-7.5 pref. 5.0-6.8, or 5.8-6.5, pref. 6.0-6.5. The **organic solvent** is selected from short-chained aliphatic, cyclic or aromatic alcohols or ketones pref. ethanol or acetone, or methanol or 2-propanol, and is added at 0.1-50% v/v, pref. 0.1-30%, esp. 0.5-10 molZn(2+)/mol. GH, pref. 1.1-2.2, esp. 1.2-2.0. The temp. is pref. 4-25 deg.C. The molar ratio of Zn(2+):GH is 0.2:10, pref. 0.5:5, pref. 0.5:2.0.

USE/ADVANTAGE - The process is used as a purificn. and/or isolation step in the mfr. of GH used in pharmaceutical prepsns. GHs derived from humans, bovines, porcines, ovines, salmon, trout or tuna may be purified, pref. humans. The process is fast, efficient and downstream, and as the crystals are highly stable they are produced ready to use without need for reconstitution.

ABEQ EP 540582 B UPAB: 19941010

A process for production of **cation** crystals of GH or of GH derivatives, comprising the following steps: a) to a solution of GH or derivatives thereof is added **cations** of inorganic or organic nature and an **organic solvent** or a mixture of **organic solvents** at a pH between 5.0 and 6.8; b) growing of crystals at a temperature from about 0 to about 30 deg.C; and c) isolation of the **cation** crystals by known means.
Dwg.0/1

L103 ANSWER 28 OF 29 IFIPAT COPYRIGHT 2003 IFI

AN 3010123 IFIPAT;IFIUDB;IFICDB

TITLE: **GROWTH HORMONE CRYSTALS**
AND A PROCESS FOR PRODUCTION OF **GROWTH HORMONE CRYSTALS**; ADDING **ORGANIC SOLVENT** MIXTURE CONTAINING DIVALENT METAL **CATION** TO SOLUTION OF **GROWTH HORMONE** TO PRECIPITATE STORAGE STABLE **CRYSTALS** AT TEMPERATURE BETWEEN 0 AND 30 DEGREES CELSIUS AND AT PH 5.8-6.5
INVENTOR(S): Junker, Flemming, Humleb ae k, DK
Theisen, Claus Friss, Kobenhavn, DK
PATENT ASSIGNEE(S): Novo Nordisk A/S, Bagsvaerd, DK
PRIMARY EXAMINER: Sayala, Chhaya D
AGENT: Gregg, Esq., Valeta
Zelson, Esq., Steve T.

	NUMBER	PK	DATE
PATENT INFORMATION:	US 5780599		19980714
	(CITED IN 001 LATER PATENTS)		
APPLICATION INFORMATION:	US 1994-350758		19941207
EXPIRATION DATE:	14 Jul 2015		

	APPLN. NUMBER	DATE	GRANTED PATENT NO. OR STATUS
CONTINUATION OF:	US 1993-961932	19930113	ABANDONED
CONTINUATION OF:	US 1994-222515	19940401	ABANDONED

	NUMBER	DATE
PRIORITY APPLN. INFO.:	DK 1990-1687	19900713
FAMILY INFORMATION:	US 5780599	19980714
DOCUMENT TYPE:	UTILITY	
FILE SEGMENT:	CHEMICAL	
	GRANTED	
NUMBER OF CLAIMS:	23	

GRAPHICS INFORMATION: 1 Drawing Sheet(s), 1 Figure(s).

AB A method of producing chemically stable and biologically active

growth hormone crystals and processes for
production of pharmaceutical preparations containing these **growth
hormone crystals**.

CLMN 23

GI 1 Drawing Sheet(s), 1 Figure(s).

L103 ANSWER 29 OF 29 USPAT2

ACCESSION NUMBER: 2001:114668 USPAT2

TITLE: Carbohydrate crosslinked glycoprotein crystals

INVENTOR(S): Margolin, Alexey L., Newton, MA, United States
Govardhan, Chandrika Poorna, Lexington, MA, United States

Visuri, Kalevi, Kantvik, FINLAND

Uotila, Sinikka, Espoo, FINLAND

PATENT ASSIGNEE(S): Altus Biologies, Inc., Cambridge, MA, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6359118	B2	20020319
APPLICATION INFO.:	US 1999-314717		19990519 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-926279, filed on 5 Sep 1997, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Low, Christopher S. F.		
ASSISTANT EXAMINER:	Mohamed, Abdel A.		
LEGAL REPRESENTATIVE:	Fish & Neave, Haley, Jr., James F., Pierri, Margaret A.		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	1888		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the field of carbohydrate crosslinked glycoprotein crystals. Advantageously, such crosslinked glycoprotein crystals display stability to harsh environmental conditions, while maintaining the structural and functional integrity of the glycoprotein backbone. According to one embodiment, this invention relates to methods for concentrating proteins that have been modified by carbohydrates and for releasing their activity at controlled rates. This invention also provides methods for producing carbohydrate crosslinked glycoprotein crystals and methods for using them in pharmaceutical formulations, vaccines, immunotherapeutics, personal care compositions, including cosmetics, veterinary pharmaceutical compositions and vaccines, foods, feeds, diagnostics, cleaning agents, including detergents and decontamination formulations. The physical and chemical characteristics of carbohydrate crosslinked glycoprotein crystals render them particularly useful as sorbents for separations, such as chiral chromatography, or affinity chromatography--which are based on specific interactions between the active binding site of the glycoprotein component of the crystals and the substance or molecule of interest. Such characteristics also render carbohydrate crosslinked glycoprotein crystals useful as catalytic and binding components for the production of biosensing devices.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=>